Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Loftus EV Jr"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-17 z 17
    Tytuł:
    Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
    Autorzy:
    Peyrin-Biroulet L; Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy, France.; University of Lorraine, Inserm, NGERE, Nancy, France.
    Ghosh S; APC Microbiome Ireland, University College Cork, Cork, Ireland.
    Lee SD; University of Washington, Seattle, Washington, USA.
    Lee WJ; AbbVie Inc., North Chicago, Illinois, USA.
    Griffith J; AbbVie Inc., North Chicago, Illinois, USA.
    Wallace K; AbbVie Inc., North Chicago, Illinois, USA.
    Berg S; AbbVie Inc., North Chicago, Illinois, USA.
    Liao X; AbbVie Inc., North Chicago, Illinois, USA.
    Panes J; Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
    Loftus EV Jr; Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
    Louis E; University Hospital CHU of Liège, Liège, Belgium.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Mar; Vol. 57 (5), pp. 496-508. Date of Electronic Publication: 2022 Oct 20.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Crohn Disease*/drug therapy
    Crohn Disease*/chemically induced
    Inflammatory Bowel Diseases*/drug therapy
    Humans ; Quality of Life ; Antibodies, Monoclonal/adverse effects ; Fatigue/chemically induced ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Autorzy:
    Bohm M; Indianapolis, IN, USA.
    Xu R; La Jolla, CA, USA.
    Zhang Y; La Jolla, CA, USA.
    Varma S; Indianapolis, IN, USA.
    Fischer M; Indianapolis, IN, USA.
    Kochhar G; Cleveland, OH, USA.
    Boland B; La Jolla, CA, USA.
    Singh S; La Jolla, CA, USA.
    Hirten R; New York, NY, USA.
    Ungaro R; New York, NY, USA.
    Shmidt E; Minneapolis, MN, USA.
    Lasch K; Deerfield, IL, USA.
    Jairaith V; London, ON, Canada.
    Hudesman D; New York, NY, USA.
    Chang S; New York, NY, USA.
    Lukin D; New York, NY, USA.
    Swaminath A; New York, NY, USA.
    Sands BE; New York, NY, USA.
    Colombel JF; New York, NY, USA.
    Kane S; Rochester, MN, USA.
    Loftus EV Jr; Rochester, MN, USA.
    Shen B; Cleveland, OH, USA.
    Siegel CA; Lebanon, NH, USA.
    Sandborn WJ; La Jolla, CA, USA.
    Dulai PS; La Jolla, CA, USA.
    Pokaż więcej
    Corporate Authors:
    VICTORY Collaboration
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Aug; Vol. 52 (4), pp. 669-681. Date of Electronic Publication: 2020 Jul 13.
    Typ publikacji:
    Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Crohn Disease/*drug therapy
    Tumor Necrosis Factor Inhibitors/*therapeutic use
    Adalimumab/therapeutic use ; Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Certolizumab Pegol/therapeutic use ; Cohort Studies ; Crohn Disease/epidemiology ; Female ; Humans ; Infliximab/therapeutic use ; Middle Aged ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/adverse effects ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
    Autorzy:
    Dulai PS; La Jolla, CA, USA.
    Amiot A; Creteil, France.
    Peyrin-Biroulet L; Nancy, France.
    Jairath V; London, ON, Canada.
    Serrero M; Marseille, France.
    Filippi J; Nice, France.
    Singh S; La Jolla, CA, USA.
    Pariente B; Lille, France.
    Loftus EV Jr; Rochester, MN, USA.
    Roblin X; Saint-Etienne, France.
    Kane S; Rochester, MN, USA.
    Buisson A; Clermont-Ferrand, France.
    Siegel CA; Lebanon, NH, USA.
    Bouhnik Y; Clichy, France.
    Sandborn WJ; La Jolla, CA, USA.
    Lasch K; Deerfield, IL, USA.
    Rosario M; Deerfield, IL, USA.
    Feagan BG; London, ON, Canada.
    Bojic D; Zurich, Switzerland.
    Trang-Poisson C; Nantes, France.
    Shen B; Cleveland, OH, USA.
    Altwegg R; Montpellier, France.
    Sands BE; New York, NY, USA.
    Colombel JF; New York, NY, USA.
    Carbonnel F; Paris, France.
    Pokaż więcej
    Corporate Authors:
    GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Mar; Vol. 51 (5), pp. 553-564. Date of Electronic Publication: 2019 Dec 22.
    Typ publikacji:
    Journal Article; Observational Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Decision Support Systems, Clinical*
    Patient Selection*
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Crohn Disease/*drug therapy
    Drug Monitoring/*standards
    Gastrointestinal Agents/*therapeutic use
    Adult ; Algorithms ; Calibration ; Cohort Studies ; Crohn Disease/epidemiology ; Drug Monitoring/methods ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease.
    Autorzy:
    Lightner AL; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    McKenna NP; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    Tse CS; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Hyman N; Division of Colon and Rectal Surgery, University of Chicago, Chicago, IL, USA.
    Smith R; Division of Colon and Rectal Surgery, University of Chicago, Chicago, IL, USA.
    Ovsepyan G; Division of Colon and Rectal Surgery, Cedars-Sinai, Los Angeles, CA, USA.
    Fleshner P; Division of Colon and Rectal Surgery, Cedars-Sinai, Los Angeles, CA, USA.
    Crowell K; Division of Colon and Rectal Surgery, Pennsylvania State Hershey Medical Center, Hershey, PA, USA.
    Koltun W; Division of Colon and Rectal Surgery, Pennsylvania State Hershey Medical Center, Hershey, PA, USA.
    Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
    D'Hoore A; Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.
    Lauwers N; Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.
    Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
    Spinelli A; Division of Colon and Rectal Surgery, Humanitas University, Rozzano, Milan, Italy.
    DiCandido F; Division of Colon and Rectal Surgery, Humanitas University, Rozzano, Milan, Italy.
    Raffals LE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Mathis KL; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 402-407.
    Typ publikacji:
    Comparative Study; Journal Article
    MeSH Terms:
    Crohn Disease/*drug therapy
    Gastrointestinal Agents/*therapeutic use
    Surgical Wound Infection/*etiology
    Tumor Necrosis Factor-alpha/*antagonists & inhibitors
    Ustekinumab/*therapeutic use
    Abdomen/surgery ; Adult ; Female ; Humans ; Ileus/etiology ; Immunologic Factors/therapeutic use ; Male ; Middle Aged ; Patient Readmission ; Reoperation ; Retrospective Studies ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series.
    Autorzy:
    Braga Neto MB; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Gregory M; Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
    Ramos GP; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Ciorba MA; Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
    Bruining DH; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Bazerbachi F; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Abu Dayyeh BK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Kushnir VM; Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
    Shah M; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA.
    Collazo-Clavell ML; Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA.
    Raffals LE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Deepak P; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.; Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
    Pokaż więcej
    Źródło:
    Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 452-457.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Bariatric Surgery*/methods
    Colitis, Ulcerative/*epidemiology
    Crohn Disease/*epidemiology
    Adult ; Age Factors ; Databases, Factual ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Sex Factors ; United States/epidemiology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
    Autorzy:
    Lightner AL; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    McKenna NP; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    Tse CS; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Raffals LE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Mathis KL; Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Mar; Vol. 47 (5), pp. 573-580. Date of Electronic Publication: 2017 Dec 18.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Abdomen/*surgery
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Crohn Disease/*drug therapy
    Crohn Disease/*surgery
    Postoperative Complications/*epidemiology
    Adolescent ; Adult ; Aged ; Cohort Studies ; Crohn Disease/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Postoperative Complications/etiology ; Postoperative Period ; Retrospective Studies ; Surgical Wound Infection/epidemiology ; Surgical Wound Infection/etiology ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Autorzy:
    Singh S; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
    Andersen NN; Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.
    Andersson M; Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.
    Loftus EV Jr; Divison of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Jess T; Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark.; Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Mar; Vol. 47 (5), pp. 596-604. Date of Electronic Publication: 2017 Dec 14.
    Typ publikacji:
    Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Adalimumab/*therapeutic use
    Crohn Disease/*drug therapy
    Infliximab/*therapeutic use
    Adult ; Biological Products/therapeutic use ; Cohort Studies ; Crohn Disease/epidemiology ; Denmark/epidemiology ; Female ; Humans ; Immunologic Factors/therapeutic use ; Male ; Middle Aged ; Registries ; Treatment Outcome ; Tumor Necrosis Factor-alpha/therapeutic use ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Antibiotic Use and New-Onset Inflammatory Bowel Disease in Olmsted County, Minnesota: A Population-Based Case-Control Study.
    Autorzy:
    Aniwan S; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.; Division of Gastroenterology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
    Tremaine WJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
    Raffals LE; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
    Kane SV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
    Pokaż więcej
    Źródło:
    Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 24; Vol. 12 (2), pp. 137-144.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Anti-Bacterial Agents/*therapeutic use
    Colitis, Ulcerative/*epidemiology
    Crohn Disease/*epidemiology
    Adolescent ; Adult ; Age of Onset ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/administration & dosage ; Case-Control Studies ; Child ; Child, Preschool ; Female ; Humans ; Incidence ; Infant ; Male ; Middle Aged ; Minnesota/epidemiology ; Odds Ratio ; Risk Factors ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Long-term Efficacy of Vedolizumab for Crohn's Disease.
    Autorzy:
    Vermeire S; University Hospitals Leuven, Belgium.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
    Colombel JF; Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York, USA.
    Feagan BG; Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
    Sandborn WJ; University of California San Diego and UC San Diego Health System, La Jolla, California, USA.
    Sands BE; Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, New York, USA.
    Danese S; Istituto Clinico Humanitas, Milan, Italy.
    D'Haens GR; Academic Medical Center, Amsterdam, The Netherlands.
    Kaser A; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
    Panaccione R; Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada.
    Rubin DT; University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
    Shafran I; Shafran Gastroenterology Center, Winter Park, Florida, USA.
    McAuliffe M; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
    Kaviya A; Takeda Development Centre Europe Ltd, London, UK.
    Sankoh S; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
    Mody R; Takeda Pharmaceuticals International, Inc., Deerfield, Illinois, USA.
    Abhyankar B; Takeda Development Centre Europe Ltd, London, UK.
    Smyth M; Takeda Development Centre Europe Ltd, London, UK.
    Pokaż więcej
    Źródło:
    Journal of Crohn's & colitis [J Crohns Colitis] 2017 Apr 01; Vol. 11 (4), pp. 412-424.
    Typ publikacji:
    Journal Article; Randomized Controlled Trial
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Crohn Disease/*drug therapy
    Gastrointestinal Agents/*therapeutic use
    Adult ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Double-Blind Method ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Male ; Quality of Life ; Remission Induction ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease.
    Autorzy:
    Singh S; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
    Ding NS; Department of Gastroenterology, St. Mark's Hospital, North West London Hospitals NHS Trust, Harrow, UK.
    Mathis KL; Division of Colorectal Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
    Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
    Farrell AM; Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA.
    Pemberton JH; Division of Colorectal Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
    Hart AL; Department of Gastroenterology, St. Mark's Hospital, North West London Hospitals NHS Trust, Harrow, UK.
    Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2015 Oct; Vol. 42 (7), pp. 783-92. Date of Electronic Publication: 2015 Aug 11.
    Typ publikacji:
    Journal Article; Meta-Analysis; Review; Systematic Review
    MeSH Terms:
    Ileostomy*/adverse effects
    Ileostomy*/methods
    Ileostomy*/rehabilitation
    Ileostomy*/statistics & numerical data
    Anus Diseases/*surgery
    Crohn Disease/*surgery
    Anus Diseases/epidemiology ; Anus Diseases/pathology ; Colectomy/adverse effects ; Colectomy/statistics & numerical data ; Crohn Disease/epidemiology ; Crohn Disease/pathology ; Feces ; Humans ; Proctocolectomy, Restorative/statistics & numerical data ; Recurrence
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
    Autorzy:
    Moon W; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.; Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
    Pestana L; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Becker B; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Hanson KA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Bruining DH; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Tremaine WJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Kane SV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2015 Aug; Vol. 42 (4), pp. 428-40. Date of Electronic Publication: 2015 Jun 17.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Certolizumab Pegol/*therapeutic use
    Crohn Disease/*drug therapy
    Rectal Fistula/*pathology
    Adalimumab/therapeutic use ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological Products/therapeutic use ; Certolizumab Pegol/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Tertiary Care Centers ; Treatment Outcome ; United States ; United States Food and Drug Administration ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
    Autorzy:
    Sandborn WJ; University of California San Diego School of Medicine, La Jolla, CA, USA.
    Melmed GY; The Widjaja Foundation Inflammatory Bowel and Immunology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
    McGovern DP; The Widjaja Foundation Inflammatory Bowel and Immunology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
    Loftus EV Jr; Mayo Clinic, Rochester, MN, USA.
    Choi JM; UCLA Center for Inflammatory Bowel Diseases, Los Angeles, CA, USA.
    Cho JH; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    Abraham B; Houston Methodist, Houston, TX, USA.
    Gutierrez A; Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
    Lichtenstein G; Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.
    Lee SD; University of Washington School of Medicine, Seattle, WA, USA.
    Randall CW; Gastroenterology Research of America, San Antonio, TX, USA.
    Schwartz DA; Vanderbilt University Medical Center, Nashville, TN, USA.
    Regueiro M; University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
    Siegel CA; Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
    Spearman M; UCB Pharma, Smyrna, GA, USA.
    Kosutic G; UCB Pharma, Raleigh, NC, USA.
    Pierre-Louis B; UCB Pharma, Raleigh, NC, USA.
    Coarse J; UCB Pharma, Raleigh, NC, USA.
    Schreiber S; Christian-Albrechts University at Kiel, Kiel, Germany.
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2015 Aug; Vol. 42 (3), pp. 330-42. Date of Electronic Publication: 2015 Jun 01.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Certolizumab Pegol/*therapeutic use
    Crohn Disease/*drug therapy
    Adult ; Double-Blind Method ; Female ; Humans ; Logistic Models ; Male ; Middle Aged ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis.
    Autorzy:
    Johnson DH; Divsion of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Khanna S
    Smyrk TC
    Loftus EV Jr
    Anderson KS
    Mahoney DW
    Ahlquist DA
    Kisiel JB
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2014 Jun; Vol. 39 (12), pp. 1408-17. Date of Electronic Publication: 2014 Apr 30.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Colitis, Ulcerative/*pathology
    Colon/*pathology
    Crohn Disease/*pathology
    Intestinal Mucosa/*pathology
    Adult ; Aged ; Colitis, Ulcerative/complications ; Colitis, Ulcerative/epidemiology ; Colonoscopy/methods ; Crohn Disease/complications ; Crohn Disease/epidemiology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms/epidemiology ; Neoplasms/etiology ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
    Autorzy:
    Mohabbat AB; Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
    Sandborn WJ
    Loftus EV Jr
    Wiesner RH
    Bruining DH
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2012 Sep; Vol. 36 (6), pp. 569-74. Date of Electronic Publication: 2012 Jul 10.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Liver Transplantation*
    Antibodies, Monoclonal/*therapeutic use
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Colitis, Ulcerative/*drug therapy
    Crohn Disease/*drug therapy
    Gastrointestinal Agents/*therapeutic use
    Tumor Necrosis Factor-alpha/*antagonists & inhibitors
    Adalimumab ; Adult ; Aged ; Female ; Humans ; Infliximab ; Male ; Middle Aged ; Postoperative Complications ; Risk Factors ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease.
    Autorzy:
    Tremaine WJ; Division of Gastroenterology and Hepatology, Fiterman Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. />Timmons LJ
    Loftus EV Jr
    Pardi DS
    Sandborn WJ
    Harmsen WS
    Thapa P
    Zinsmeister AR
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2007 Jun 15; Vol. 25 (12), pp. 1435-41.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Colitis, Ulcerative/*surgery
    Crohn Disease/*surgery
    Adolescent ; Adult ; Age of Onset ; Aged ; Aged, 80 and over ; Case-Control Studies ; Child ; Colitis, Ulcerative/epidemiology ; Crohn Disease/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.
    Autorzy:
    Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA. loftus. />Schoenfeld P
    Sandborn WJ
    Pokaż więcej
    Źródło:
    Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2002 Jan; Vol. 16 (1), pp. 51-60.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
    MeSH Terms:
    Crohn Disease/*epidemiology
    Crohn Disease/*pathology
    Adolescent ; Adrenal Cortex Hormones/therapeutic use ; Adult ; Age Factors ; Aged ; Child ; Child, Preschool ; Chronic Disease ; Epidemiologic Studies ; Female ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Middle Aged ; North America/epidemiology ; Population Surveillance ; Prevalence ; Sex Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-17 z 17

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies